CTOs on the Move

Bacterin International

www.comwcap.com

 
Bacterin International, Inc. is a Belgrade, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: > $1 Billion
  • www.comwcap.com
  • 664 Cruiser Ln
    Belgrade, MT USA 59714
  • Phone: 406.388.0480

Executives

Name Title Contact Details

Similar Companies

Healthcare Commons Inc

Healthcare Commons Inc is a Penns Grove, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ebenezer Ridges

Ebenezer Ridges is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concentra Inc.

Concentra Managed Care, Inc. is the leading provider of healthcare management and cost containment services to the workers' compensation, auto insurance and disability insurance markets.

Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company`s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.